NOT KNOWN FACTS ABOUT TREATMENT

Drug interactions at the moment are the best obstacle in managing HIV/HCV co-infected individuals. In terms of security results, tenofovir DF employed with ledipasvir or velpatasvir may result in a rise in serum creatinine, particularly when combined with a pharmacokinetic booster. [139] The use of tenofovir DF must be averted in these cases in the